GlassScriptPhysician profile
Erica H Lambert
NPI 1285803528
$4,974.81
in general payments reported to CMS, 2019-2025
38 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $545 · 2021: $822 · 2022: $1,161 · 2023: $1,407 · 2024: $161 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $546.86 | 2019-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $507.23 | 2021-2025 | |
| Astellas Pharma US INC | $495.55 | 2019-2023 | Myrbetriq, Veozah |
| Axonics, INC. | $396.86 | 2021-2023 | Axonics |
| Merck Sharp & Dohme LLC | $277.12 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Endo Pharmaceuticals INC. | $264.19 | 2019-2021 | |
| Boston Scientific Corporation | $251.14 | 2019-2025 | Axonics |
| Pfizer INC. | $192.96 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $184.30 | 2023 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $180.89 | 2021-2023 | Myrisk, Prolaris |
| Urovant Sciences INC | $177.12 | 2021-2022 | |
| Calyxo, INC. | $174.94 | 2025 | Cvac Aspiration System |
| Tolmar Pharmaceuticals, INC. | $150.53 | 2019-2022 | |
| Agiliti Surgical, INC. | $114.33 | 2023 | Soltive, Trinity, Sonablate |
| Accord Healthcare, INC. | $100.72 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $98.66 | 2024 | |
| Teleflex LLC | $82.61 | 2021-2023 | Urolift |
| Allergan, INC. | $77.54 | 2019-2022 | |
| Coloplast Corp | $68.02 | 2019-2023 | Speedicath |
| Neotract INC. | $61.97 | 2020 | |
| Glaxosmithkline, LLC. | $61.20 | 2023-2024 | Trelegy Ellipta |
| Tolmar, INC. | $60.25 | 2023 | |
| 180 Medical, INC. | $55.52 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $50.72 | 2023 | Yonsa |
| Davol INC. | $46.52 | 2020 | |
| Abbvie INC. | $41.66 | 2021-2023 | |
| Merz North America, INC. | $41.40 | 2024-2025 | |
| Bard Access Systems, INC. | $36.81 | 2019 | |
| Myovant Sciences INC. | $24.14 | 2022 | |
| Progenics Pharmaceuticals, INC. | $22.34 | 2022 | |
| Urogen Pharma, INC. | $19.61 | 2022 | |
| Olympus America INC. | $19.48 | 2022 | |
| Mission Pharmacal Company | $19.42 | 2019 | |
| Palette Life Sciences, INC. | $18.48 | 2023 | |
| Immunocore Limited | $17.71 | 2025 | Kimmtrak |
| Covidien LP | $15.25 | 2019 | |
| Metuchen Pharmaceuticals | $12.54 | 2019 | |
| Ambu INC. | $8.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.